Equities

Aptamer Group PLC

APTA:LSE

Aptamer Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.6495
  • Today's Change0.0245 / 3.92%
  • Shares traded1.40m
  • 1 Year change-90.38%
  • Beta--
Data delayed at least 20 minutes, as of Jul 02 2024 15:35 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Aptamer Group PLC's revenues fell -56.59% from 4.04m to 1.75m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 2.09m to a larger loss of 7.84m.
Gross margin-11.88%
Net profit margin-677.39%
Operating margin-687.73%
Return on assets-111.66%
Return on equity-187.54%
Return on investment-154.29%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Aptamer Group PLC fell by 6.46m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 4.06m for operations while cash used for investing totalled 2.03m.
Cash flow per share-0.0301
Price/Cash flow per share--
Book value per share0.0043
Tangible book value per share0.004
More ▼

Balance sheet in GBPView more

Aptamer Group PLC has a Debt to Total Capital ratio of 34.67%.
Current ratio2.14
Quick ratio2.04
Total debt/total equity0.5307
Total debt/total capital0.3467
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.